Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer
CAMBRIDGE, Mass. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M. Storer as Senior Vice President and Chief Financial Officer.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA ® (abatacept) candidate-- CAMBRIDGE, Mass. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the third quarter ended
View HTML
Toggle Summary Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 20, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2016 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® (adalimumab), Through Termination of Collaboration Agreement with Baxalta, Now Part of Shire
Shire to continue to fund the M923 program for twelve months and will transfer all remaining clinical, regulatory and commercialization activities to Momenta
View HTML
Toggle Summary Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors
CAMBRIDGE, Mass. , Sept. 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N. Fishman to its Board of Directors effective September 22,
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference
CAMBRIDGE, Mass. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results
CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2016 . For the second quarter of 2016, the Company reported total revenues of $26.4 million , including $20.7 million in
View HTML
Toggle Summary Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating
View HTML